

# An Indigenous Plant Bael (*Aegle Marmelos* (L.) Correa) Extract Protects Against the Doxorubicin-Induced Cardiotoxicity in Mice

Ganesh Chandra Jagetia\* and Ponemone Venkatesh

Department of Zoology, Mizoram University, Aizawl-796 004, India

## Abstract

Doxorubicin (DOX) is an effective antineoplastic agent widely used for the treatment of various cancers; however, its clinical use is limited due to the induction of dose-dependent toxicity in the hearts of patients receiving this drug. Therefore any agent that can reduce its myocardial toxicity will be very useful in clinics. The effect of hydroalcoholic extract of bael, *Aegle marmelos* (AME), a medicinal herb, was evaluated for its ability to reduce doxorubicin induced cardiotoxicity in mice. Based on our earlier studies 350 mg/kg AME was given to mice injected with a single dose of 15 mg/kg DOX. DOX treatment showed a significant elevation in the glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), creatine kinase (CK-MB) and lactate dehydrogenase (LDH) activities in serum of animals killed at 30 h after DOX treatment, indicating acute cardiotoxicity. Treatment of mice with AME before DOX administration significantly reduced the serum levels of CK-MB, LDH, GPT, and GOT indicating that AME protected mice against the DOX-induced acute cardiotoxicity. Pretreatment of mice with AME significantly reversed the DOX-induced decline in the antioxidant status and elevated lipid peroxidation in the myocardial tissue. In a separate experiment the effect of AME against the doxorubicin-induced cardiotoxicity was also studied by evaluating electrocardiogram and myocardial biopsies in mice administered with DDW or AME once daily for 5 consecutive days before exposure to a weekly dose of 5 mg/kg b. wt. DOX for 3 consecutive weeks. DOX treatment caused an increase in the ST interval, which was used as a measure of cardiotoxicity. AME treatment significantly reduced the ST interval indicating protection against DOX-induced chronic cardiotoxicity. The histopathological examination of heart revealed degeneration of myofibrils with mild necrosis in DOX treated group, whereas AME pretreatment drastically reduced these events in the cardiac tissue. Intraperitoneal injection of 1.25 mg/kg DOX once daily for 9 consecutive days significantly improved the survival of mice bearing Ehrlich ascites carcinoma (EAC). Treatment of EAC with 350 mg/kg AME alone did not affect the anticancer activity of DOX since AME did not alter the tumor cell growth, the median and average survival times of tumor bearing mice. The present study demonstrates that AME protects mice against the DOX-induced acute and chronic cardiotoxicity without interfering with the antineoplastic activity of DOX.


**Keywords:** *Aegle marmelos*; Doxorubicin; Cardiotoxicity; Antioxidants; Electrocardiogram; Ehrlich ascites carcinoma

## Introduction

Doxorubicin (Adriamycin), a water-soluble anthracycline antibiotic was first isolated from *Streptomyces peucetius var caesius* [1]. The DOX molecule contains an aminosugar, daunosamine, linked through a glycosidic bond to adriamycinone, a red-pigmented naphthacenequinone nucleus (Figure 1). DOX is highly lipophilic in nature and has a relatively long half-life in the body. In the chemical structure of DOX, the second ring is of special interest because of its potential for free radical generation. One electron reduction of second ring leads to the

formation of a semiquinone free radical, which is relatively stable under anaerobic condition, but donates its unpaired electron to oxygen (O<sub>2</sub>) under aerobic conditions and forms a superoxide radical [2-4]. This reaction regenerates the parental Adriamycin molecule. The sequence of reactions, known as 'redox cycling', is potentially harmful to cells since relatively little amount of DOX would be sufficient to catalyze the formation of numerous superoxide radicals. Superoxide radicals can react with hydrogen peroxide to form highly reactive hydroxyl radicals via the iron catalyzed Haber-Weiss reaction. The secondarily derived hydroxyl radicals can cause protein and DNA damage and initiate lipid peroxidation [5]. Increased lipid peroxidation, and enhanced free radical generation in the heart have been found to be the major cause of DOX induced cardiotoxicity [6]. Iron has been reported to play an important role in the DOX-induced toxicity, because the presence of iron can facilitate the generation of oxygen free radicals by the formation of DOX-iron complexes [7].

DOX is particularly effective against various disseminated neoplasms, such as lymphoblastic and myeloblastic leukaemias,



**Figure 1:** Chemical structure of adriamycin. Aminosugar is linked to tetracyclic aglycone through a glycosidic bond. Presence of quinone ring (2nd) confers radical production ability.

\*Corresponding author: Ganesh Chandra Jagetia, Department of Zoology, Mizoram University, Tanhril, Aizawl-796 004, Mizoram, India, Tel: 011-389-2330724/2330227; E-mail: [gc.jagetia@gmail.com](mailto:gc.jagetia@gmail.com)

Received April 20, 2015; Accepted May 13, 2015; Published May 20, 2015

**Citation:** Jagetia GC, Venkatesh P (2015) An Indigenous Plant Bael (*Aegle Marmelos* (L.) Correa) Extract Protects Against the Doxorubicin-Induced Cardiotoxicity in Mice. Biochem Physiol 4: 163. doi: [10.4172/2168-9652.1000163](https://doi.org/10.4172/2168-9652.1000163)

**Copyright:** © 2015 Jagetia GC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

neuroblastomas, bone marrow sarcomas, and malignant lymphomas as well as carcinomas of the breast, bladder, and thyroid [8-10]. The planar anthracycline ring of doxorubicin is capable of intercalating into DNA double helix to interfere with the reading fidelity of both DNA and RNA polymerases. It also forms sequence-specific DNA adducts that are highly susceptible to cleavage by topoisomerase II [11]. Doxorubicin (DOX) inhibits the action of topoisomerase II and stabilize a reaction, in which DNA strands are cut and covalently connected to the tyrosine residues of topoisomerase II, eventually impeding DNA resealing that results in the inhibition of DNA repair [12,13]. Regardless of the specific mechanism, DNA, RNA and protein synthesis are all inhibited, arresting cell proliferation in the G1, S-phase and G2, of the cell cycle [14,15].

Doxorubicin is typically administered as an intravenous infusion of 40–75 mg/m<sup>2</sup> repeated at 3–4 week intervals, being cautious not to exceed a cumulative dose of 450–550 mg/m<sup>2</sup>. However, the treatment of cancer patients with DOX is associated with acute toxic effects such as myelosuppression, nausea, vomiting and arrhythmias [4,16] and chronic side effects like cardiomyopathy and ultimately congestive heart failure [17,18]. The acute side effects are reversible or clinically manageable whereas chronic side effects, develop several weeks or months after repetitive doxorubicin administration, and are irreversible and have grave prognosis [19, 20].

Although several hypotheses explaining the mechanisms of anthracycline-induced cardiotoxicity have been put forward, it is generally believed to be caused by the formation of oxygen free radicals and iron ions [21,22]. In biological systems, doxorubicin is known to produce highly reactive free radicals [3] and antioxidant enzymes play a critical role in inactivating these radicals [23]. It is well known that antioxidant enzymes including superoxide dismutase and catalase are present at lower levels in the cardiomyocytes than the other tissues of the body [24], which makes cardiomyocytes particularly more susceptible to free radical damage [25,26]. Therefore, a need is felt for a drug, which can protect against DOX-induced acute and chronic cardiotoxicity without compromising with its antineoplastic activity.

A great deal of efforts has been expended in preventing or mitigating the cardiotoxic side effects of DOX. Several agents, including dexrazoxane (ICRF-187) and amifostine, have been tried, but with a limited success [27,28]. Despite its promising protective cardiovascular effects, clinical use of dexrazoxane has been seriously questioned because it is associated with severe myelosuppression, which is actually potentiated by doxorubicin [29]. The possibility that dexrazoxane may interfere with cancer therapy has also been raised [28]. The use of antioxidants to prevent DOX-induced genotoxicity and cardiotoxicity has been advocated. Strategies have been devised to prevent DOX-induced toxicity without affecting its anti-tumor activity [20].

Until more selective anticancer agents are developed, sensitive normal tissues, such as bone marrow (BM) limits the maximum tolerated doses. Thus strategies to prevent myelosuppression resulting from chemotherapy are at a high priority of research. In recent times, focus on plant research has increased all over the world and a large body of evidence has collected to show immense potential of medicinal plants used in various traditional systems. Dietary ingredients may be very useful, if they are found to protect against the deleterious effects of these antineoplastic agents on the normal tissues, as they are biocompatible, widely acceptable, and would not put an extra foreign substance into the body. Further they can be safely manipulated without toxic manifestations. Several botanicals like *Crataegus oxycantha*,

*Terminalia arjuna*, *Inula racemosa* and *Allium sativum* have been found to have therapeutic benefit for the treatment of cardiovascular diseases and its cardioprotective action has been reported in vivo [30-33]. Similarly curcumin, lycopene, tomato extract, *Phyllanthus urinaria*, *Centella asiatica* and antarth a poly herbal preparation have been reported to reduce DOX-induced cardiotoxicity in vivo [34-38]. Recently a bioflavonoid naringin has been found to protect against DOX-induced cardiotoxicity in mice [39].

*Aegle marmelos* is a spinous tree belonging to the family Rutaceae, it has been used to treat ophthalmia, ulcers, dropsy, diarrhoea, dysentery, and beriberi associated with the weakness of heart in the Ayurvedic system of Medicine in India. *Aegle* leaf extract has been reported to regenerate damaged pancreas ( $\beta$ -cells) in diabetic rats [40] and has been as effective as insulin in restoring blood glucose and body weight to normal levels [41]. Bael has been traditionally used in Ayurvedic system of medicine as a 'cardiotonic' and its effect is like digitalis for treatment of heart ailments [42,43]. In an earlier study AME has shown to inhibit the beating rate of heart and reduced the ratio of morphologically changed myocardial cells [44]. AME was also found to act as lipid-lowering agent in isoproterenol-induced myocardial infarction in rats [45]. Bael has been reported to reduce radiation and DOX-induced DNA damage [46,47] *Aegeline*, *lupeol*, and *marmesinin* active principles isolated from *A. marmelos* have been reported as cardioprotective in isoproterenol treated rats [48,49]. The common usage, its wide acceptability to human beings, diverse medicinal and antioxidative properties attributed to *Aegle marmelos* stimulated us to obtain an insight into its cardioprotective activity against the doxorubicin-induced toxicity in mice.

## Materials and Methods

### Chemicals

Doxorubicin hydrochloride (DOX) was obtained from Biochem Pharmaceutical Industries, Mumbai, India. Analytical grade cumene hydroperoxide, thiobarbituric acid (TBA), ascorbic acid, glutathione (GSH), 5,5-dithio-bis (2-nitrobenzoic acid) (DTNB), diethylenetriamine pentaacetic acid (DTPA), butylated hydroxytoluene, 1-chloro-2, 4-dinitrobenzene, ethidium bromide, 2,4-dinitrophenyl hydrazine, guanidine hydrochloride, ferric chloride, ferrous sulphate and tetraethoxypropane were procured from Sigma Chemicals Co, St. Louis, MO, USA.

### Animal Care and handling

The animal care and handling were done according to the guidelines issued by the World Health Organization, Geneva, Switzerland and the INSA (Indian National Science Academy, New Delhi, India). Eight to ten weeks old male Swiss albino mice weighing 30 to 36 g were selected from an inbred colony maintained under the controlled conditions of temperature ( $23 \pm 2^\circ$  C), humidity ( $50 \pm 5\%$ ) and light (10 and 14 h of light and dark, respectively). The animals had free access to sterile food and water throughout the study period. Four animals were housed in a polypropylene cage containing sterile paddy husk (procured locally) as bedding throughout the experiment. The study was approved by Institutional Animal Ethical Committee (IAEC) of Kasturba Medical College, Manipal, where the study was carried out.

### Extraction of AME

*Aegle marmelos* (L.) Correa was identified by Dr. Gopal Krishna Bhat, (a well known taxonomist) Department of Botany, Poorna Prajna College, Udupi, India. Mature leaves of the *Aegle marmelos* were

collected locally during January-February of the year, cleaned, shade dried, powdered, and extracted [50]. Briefly, one hundred grams of the leaf powder was extracted with 50% ethanol at 50 to 60°C in a Soxhlet apparatus for 72 h. The cooled extract was concentrated to dryness in a lyophilizer. A 24% yield of the extract was obtained. The extract was stored at -70°C until use. Henceforth, the extract of *Aegle marmelos* will be called as AME.

### Mode of administration

AME or doxorubicin hydrochloride (DOX) was dissolved in double distilled water (DDW), immediately before use. The animals were administered with 0.01 ml/g body weight of double distilled water (DDW) or 350 mg/kg b. wt. of AME orally (p.o.) once daily for five consecutive days using oral feeding needles (Popper & Sons Inc., New York, USA) before exposure to DOX.

### Experimental

The male Swiss albino mice were divided into the following groups. A total of four animals (n = 4 animals in each group) were used in each group.

**Acute cardiotoxicity:** A separate experiment was carried out to evaluate the cardioprotective activity of bael, where the animals were divided into various groups as follows:

**DDW group:** The animals of this group were administered with 0.01 ml/g b. wt. of double distilled water, orally once daily for 5 consecutive days.

**AME group:** The animals of this group were administered with 350 mg/kg b. wt. of AME orally once daily for 5 consecutive days.

**DOX group:** The animals of this group received double distilled water, orally once daily for 5 consecutive days, and one hour after the last treatment, the animals of this group received single dose of 15 mg/kg b. wt. DOX intraperitoneally.

**AME + DOX group:** Animals of this group were administered with 350 mg/kg b. wt. of AME orally once daily for 5 consecutive days, and one hour after the last treatment, animals received a single dose of 15 mg/kg b. wt. DOX intra-peritoneally.

**Serum marker enzymes:** The mice were killed by decapitation 30 h after DOX treatment. The blood was collected by cardiac puncture, the sera were separated by centrifugation at 5000 rpm for 10 min and frozen at -70°C for estimation of lactate dehydrogenase (LDH) [51], creatine kinase isoenzyme (CK-MB) [52], glutamic pyruvic transaminase (GPT) and glutamic oxaloacetic transaminase (GOT) [53].

**Antioxidant activity:** A separate experiment was conducted to evaluate the antioxidant potential of AME *in vivo* by dividing the animals into four groups as described above. The mice of all groups were killed at 0, 0.5, 1 and 2 h after DOX treatment by cervical dislocation. The hearts were perfused with cold PBS, removed, blot dried, weighed, homogenized in 50 mM ice cold saline (pH 7.4), and centrifuged for 5 min at 5000 g. The samples were stored at -70°C for biochemical estimations. The total proteins were measured by the modified method of Lowry [54]. The product of lipid peroxidation was measured as thiobarbituric acid reactive substances (TBARS) [55]. The activities of glutathione content [56], superoxide dismutase [57], catalase [58] and glutathione peroxidase [59] activities were determined.

**Chronic cardiotoxicity:** A separate experiment was carried out to study chronic DOX-induced cardiotoxicity where the grouping

and other conditions of the experiment was essentially similar to that described in experimental section, except that mice received a single dose of 5 mg/kg DOX once a week for 3 weeks (DOX group), whereas animals of AME + DOX group received 350 mg/kg AME once daily for 5 consecutive days. One hour after the last AME treatment, the mice were administered with first dose of 5 mg/kg DOX. Thereafter a similar regimen was followed for another two weeks. Animals were monitored for 2 weeks after the last administration of DOX and subjected to ECG on the last day of observation. After recording the ECG animals were killed and their hearts removed for histopathological examination.

**Electrocardiogram (ECG):** ECG recording in mice was carried out by placing the animals under anesthesia (ether), where a mouse was kept in the supine position, and four-lead ECGs were recorded from subcutaneous 18-gauge needle electrodes implanted subcutaneously into each limb. The ECG was recorded on a Cardiart (BPL, Cardiart 108T-MK VII Instruments, AC 110 ~ 230V, 50 Hz) with a recording speed of 25 mm/s. Heart rates were calculated by counting beats from 15 sec of electrocardiogram recording and expressed as beats per minute (bpm).

**Histopathology:** Histopathological evaluation of heart of each treatment group was carried out according to the method of Billingham [60] and modified by Gabrielson et al. [61]. The hearts were fixed in phosphate-buffered 10% formalin, embedded in paraffin, sectioned (ventricular sections) at a thickness of 5 nm, and stained with hematoxylin and eosin. Qualitative analysis of heart sections was carried out under a transmitted light microscope (Photomicroscope III, Carl Zeiss, Oberkohn, Germany).

### Effect of AME in conjunction with DOX in tumor bearing mice

A separate experiment was carried out to evaluate the effect of AME on the alteration in the antitumor activity of doxorubicin in the Ehrlich ascites carcinoma (EAC) bearing mice, treated with the combination of AME and DOX.

**Tumor model:** Ehrlich ascites carcinoma (EAC) procured from Cancer Research Institute (ACTREC), Mumbai, India was maintained and propagated by serial intraperitoneal transplantation into the Swiss albino mice in an aseptic environment. No spontaneous regression of EAC was observed throughout the study. The experiments were carried out by injecting 10<sup>6</sup> viable EAC cells into each animal intraperitoneally in sterile conditions and the day of tumor inoculation was considered as day 0.

The animals were divided into the following groups one day after tumor inoculation:

**DDW group:** The animals of this group received double distilled water, consecutively for 9 days.

**DOX group:** This group of animals was injected with 1.25 mg/kg b. wt. of DOX dissolved in sterile saline, 24 hours after tumor inoculation, consecutively for 9 days and served as positive control.

**AME group:** The animals of this group were administered p. o. with 350 mg/kg b. wt. AME 24 hours after tumor inoculation, once daily consecutively for 9 days.

**AME + DOX group:** The animals of this group were administered p.o. with 350 mg/kg b. wt. AME, 24 hours after tumor inoculation, and one hour before the administration of DOX, once daily consecutively for 9 days.



After the last administration of drug(s) the animals were monitored regularly for body weight changes signs of toxicity and mortality. The weight of animals was recorded every third day up to 30 days after tumor inoculation in all the groups. The tumor response of DOX was assessed on the basis of median survival time (MST) and tumor free survival. The increase in median life span (% IMLS) and increase in average life span (% IALS) were also calculated [62].

**Statistical analysis:** The significance between the treatments was determined using students't-test for cardiotoxicity and one-way analysis of variance (ANOVA) for antioxidant activity, while the log rank test was applied for survival assay of tumor bearing mice.

## Results

### Acute Cardiotoxicity

**Serum marker enzymes:** Table 1 shows the effect of AME on DOX induced biochemical changes in the serum of mice. Treatment of mice with DOX significantly elevated the activities of GOT, GPT, LDH and CK-MB by more than 2 folds indicating drug-induced cardiotoxicity. Administration of 350 mg/kg b. wt. AME once daily for 5 consecutive days before DOX treatment significantly inhibited the increase in the activities of these enzymes in the serum of AME + DOX group (Table 1).

### Antioxidant activity

**Myocardial lipid peroxidation:** Lipid peroxidation was measured as thiobarbituric acid reactive substances (TBARS). AME administration alone resulted in a significant ( $p < 0.05$ ) reduction in the baseline activity of TBARS in mice hearts (Table 2). The doxorubicin

treatment resulted in a significant elevation in TBARS and the greatest elevation was observed at 30 min post-doxorubicin treatment. The AME administration before doxorubicin treatment caused a significant reduction in TBARS at all the post-treatment assay times (Table 2).

**Myocardial glutathione:** Treatment of mice with AME alone significantly ( $p < 0.05$ ) elevated the baseline GSH level at all post-treatment times when compared with the non-drug treated control group. Treatment of mice with DOX caused a significant decline in the GSH contents at all the post-treatment times. The lowest concentration of glutathione was observed at 30 min (Table 2). Treatment of mice with AME before DOX treatment significantly elevated the GSH concentration at all post-treatment times (Table 2).

**Myocardial catalase:** Treatment of mice with AME caused a significant elevation in the spontaneous level of catalase at all post-treatment times in the heart of mice (Table 2). Doxorubicin treatment caused a significant decline in the catalase activity, whereas AME treatment resulted in a significant increase ( $p < 0.05$ ) in the activity of myocardial catalase when compared to DOX alone (Table 2). The catalase activity also increased with increase in assay time up to 1 h (Table 2).

**Myocardial Superoxide dismutase:** AME treatment alone did not significantly alter the baseline activity of SOD at all the post-treatment assay times. The doxorubicin treatment caused a non-significant decline in the SOD activity when compared to the baseline activity (Table 2) and maximum reduction IN SOD activity was observed at 30 min post-treatment (Table 2). AME treatment before DOX administration showed a non-significant elevation ( $p < 0.01$ ) in SOD activity in the hearts of mice where normal levels could be observed as early as 30 min post-treatment when compared with the DOX treatment alone.

**Myocardial glutathione peroxidase (GSHPx):** AME pretreatment did not significantly alter the baseline activity of GSHPx. A significant ( $p < 0.05$ ) reduction in GSHPx activity was observed in the heart of mice receiving DOX treatment alone (Table 2). The myocardial tissue showed a significant ( $p < 0.05$ ) elevation in GSHPx activity in mice treated with AME before DOX administration. There was a time dependent marginal elevation of GSHPx in the AME + DOX group (Table 2).

### Cardioprotective effect against chronic toxicity

**Electrocardiogram (ECG) studies:** The ECG signal in lead II deflection of a mouse is somewhat different from that of man [63]. The ECGs of the control animals did not alter during the course of

Treatment	Serum enzyme levels (IU/ml) $\pm$ SEM			
	CK-MB	LDH	GOT	GPT
Control	6.72 $\pm$ 0.38	164.92 $\pm$ 2.3	32.43 $\pm$ 1.39	8.94 $\pm$ 0.62
DDW + AME	6.58 $\pm$ 0.40	162.8 $\pm$ 2.15	32.64 $\pm$ 2.50	10.42 $\pm$ 1.21
DDW + DOX	17.45 $\pm$ 1.72 <sup>c</sup>	214.2 $\pm$ 4.26 <sup>c</sup>	74.71 $\pm$ 2.64 <sup>c</sup>	23.26 $\pm$ 1.36 <sup>c</sup>
AME + DOX	10.16 $\pm$ 1.08 <sup>a</sup>	185.4 $\pm$ 3.72 <sup>b</sup>	51.29 $\pm$ 2.12 <sup>b</sup>	18.84 $\pm$ 0.74 <sup>c</sup>

Values are mean  $\pm$  standard error of the mean (SEM) of four experiments. a =  $p < 0.05$ , b =  $p < 0.01$  and c =  $p < 0.001$ . No symbols = non-significant.

**Table 1:** Effect of AME on the levels of cardiac enzymes in mice treated with doxorubicin.


Time (h)	Group	TBARS (nMol/ gm tissue)	GSH (ug/gm tissue)	Catalase (U/mg protein)	SOD (U/mg protein)	GSHPx (U/mg protein)
0.5	Control	82.4 $\pm$ 3.2	1.03 $\pm$ 0.02	14.32 $\pm$ 0.4	5.82 $\pm$ 3.2	0.14 $\pm$ 0.03
	DDW+AME	73.2 $\pm$ 3.7 <sup>a</sup>	1.26 $\pm$ 0.04 <sup>c</sup>	18.14 $\pm$ 0.3 <sup>b</sup>	5.74 $\pm$ 2.4 <sup>a</sup>	0.15 $\pm$ 0.01
	DDW+DOX	185.2 $\pm$ 6.4 <sup>c</sup>	0.43 $\pm$ 0.03	8.42 $\pm$ 0.42 <sup>c</sup>	4.12 $\pm$ 0.9	0.092 $\pm$ 0.03
	AME+DOX	128.4 $\pm$ 9.2 <sup>b</sup>	0.82 $\pm$ 0.03 <sup>a</sup>	11.56 $\pm$ 0.3 <sup>a</sup>	5.32 $\pm$ 1.5	1.10 $\pm$ 0.01 <sup>c</sup>
1	Control	85.2 $\pm$ 3.2	1.06 $\pm$ 0.04	14.94 $\pm$ 0.5	5.82 $\pm$ 0.8	0.14 $\pm$ 0.03
	DDW+AME	76.4 $\pm$ 2.7 <sup>a</sup>	1.24 $\pm$ 0.02 <sup>c</sup>	18.32 $\pm$ 0.2 <sup>c</sup>	5.84 $\pm$ 1.2 <sup>b</sup>	0.14 $\pm$ 0.02
	DDW+DOX	168.6 $\pm$ 4.4 <sup>c</sup>	0.48 $\pm$ 0.04	10.64 $\pm$ 0.5 <sup>c</sup>	4.46 $\pm$ 0.7	0.096 $\pm$ 0.02
	AME+DOX	108.2 $\pm$ 6.3 <sup>a</sup>	0.96 $\pm$ 0.02 <sup>a</sup>	12.72 $\pm$ 0.4 <sup>a</sup>	5.41 $\pm$ 1.2 <sup>a</sup>	1.11 $\pm$ 0.01 <sup>a</sup>
2	Control	84.0 $\pm$ 3.2	1.04 $\pm$ 0.02	14.32 $\pm$ 0.3	5.78 $\pm$ 2.1	0.14 $\pm$ 0.02
	DDW+AME	72.4 $\pm$ 3.8 <sup>a</sup>	1.26 $\pm$ 0.03 <sup>c</sup>	16.42 $\pm$ 0.6 <sup>c</sup>	5.86 $\pm$ 1.2 <sup>a</sup>	0.15 $\pm$ 0.01
	DDW+DOX	149.2 $\pm$ 4.5 <sup>c</sup>	0.51 $\pm$ 0.03	10.94 $\pm$ 0.31 <sup>c</sup>	4.32 $\pm$ 1.1	0.097 $\pm$ 0.03
	AME+DOX	96.4 $\pm$ 3.2 <sup>b</sup>	0.98 $\pm$ 0.03 <sup>a</sup>	13.6 $\pm$ 0.94 <sup>a</sup>	5.14 $\pm$ 1.3	1.13 $\pm$ 0.02 <sup>c</sup>

Values are mean  $\pm$  standard error of the mean (SEM) of four experiments. a =  $p < 0.05$ , b =  $p < 0.01$  and c =  $p < 0.001$ . No symbols = non-significant.


**Table 2:** Effect of AME on the antioxidant contents of mice heart tissue treated with doxorubicin.

the study. Doxorubicin had a profound influence on the shape of the ECG (Figure 2). The ST interval increased with time by  $3.6 \pm 1.2$  ms. AME treatment was found to protect mice against DOX-induced ECG changes, and reduced the DOX-induced increase in the ST interval to  $1.45 \pm 0.8$  ms ( $P < 0.001$ ) relative to DOX treatment alone, which is not significantly different from control (Figure 3). In all the animals the maximum heart rate was 650-700 bpm during the entire study.


**Histopathology studies :** Marked tissue injury with subendocardial loss of muscles and accumulation of acute inflammatory cells surrounded by mild edema along with degeneration of myofibrils and vacuolization of a few myocardial cells were seen in DOX group (Figure 4). DOX treatment alone showed multiple necrosis of myofibrils,



**Figure 2:** Alterations in the electrocardiograms (ECG) of mice treated with or without AME before exposure to DOX. a: control mice; b: DOX alone; c: AME + DOX.



**Figure 3:** Alteration in ST interval in ECG of mice treated with or without AME 350 mg/kg b. wt./week DOX intraperitoneally for 3 weeks.



**Figure 4:** Effect of *Aegle marmelos* extract (AME) on the doxorubicin (DOX)-induced myocardiotoxicity in mice. Upper left: Control; Upper right: AME alone; Lower left: DOX and Lower right: AME+DOX.

whereas AME pretreatment reduced DOX-induced changes in the cardiomyocytes (Figure 4).

#### Effect of AME on antineoplastic action of DOX

The effects of AME on the antitumor efficacy of DOX, was assessed in mice bearing Ehrlich ascites carcinoma. No spontaneous regression was observed in the mouse injected with EAC cells during the study period and the animals exhibited a constant increase in the weight due to tumor cell multiplication. The first death was observed on day

14 and all the control animals died by day 23 post-tumor inoculation (Figure 5-6). The median survival time (MST) and the average survival time (AST) were found to be 19 and 18.5 days, respectively (Table 3). Treatment of 1 day old tumors with 1.25 mg/kg DOX inhibited weight gain in animals indicating arrest of tumor cell proliferation and growth (Table 3). DOX treatment increased the MST and AST up to 35.6 and 34 days, respectively accompanied by an increase in the mean life span (IMLS) and the average life span (IALS) up to 87.3% and 83.7%, respectively. Treatment of 1 day old tumors with 350 mg/kg AME alone did not inhibit weight gain in animals indicating that drug as such did not affect tumor cell multiplication and growth. The MST of 22.5 and AST of 21 days remained unaltered in the AME group when compared with the control group (Table 3). Similarly, treatment of EAC mice with 350 mg/kg of AME before administration of 1.25 mg/kg DOX did not significantly alter the MST of 34 and AST of 33 days when compared with the DOX group treatment alone indicating that AME did not

Group	MST		AST	IMLS	IALS
	Days				
Control	19	18.5	-	-	-
DDW+AME	22.5	21	18.4	13.5	
DDW+DOX	35.6	34	87.3	83.7	
AME+DOX	34	32.6	78.9	76.2	


**Table 3:** Effect of AME on median survival time (MST) and average survival time (AST) of EAC mice treated with DOX.

interfere with the antineoplastic activity of DOX (Table 3). A similar effect was noticed for the increase in mean life span (IMLS) and the average life span (IALS) that remained unaltered to 78.9 % and 76.2 %, respectively (Table 3).


## Discussion

The use of cytoprotective agents represents an alternative strategy to reduce radio- and chemotherapeutic toxicity in normal tissues [64,65], which will prevent the risk of potentially genotoxic effects leading to secondary tumor formation [66]. For those agents whose maximum tolerated dose is limited primarily by myelosuppression, several strategies are under evaluation to permit dose escalation in the hope of obtaining better clinical results with currently available chemotherapeutic drugs. The major acute toxicity induced by DOX is bone marrow suppression, and its long-term clinical usefulness is limited by a cumulative dose-dependent irreversible chronic cardiotoxicity, which manifests itself as congestive heart failure or cardiomyopathy [65,67]. Therefore, it is essential to screen chemical agents that can protect the normal cells against DOX-induced cumulative toxicity without compromising its neoplastic activity. Plants by virtue of their wide usage in the traditional medicine and less toxic implications have attracted the attention of researchers around the world and WHO has recognized complimentary and alternative medicine as part of treatment modalities. The herbal drugs have been used since time immemorial to treat various disorders and offer an alternative to the synthetic drugs, as they have been considered either nontoxic or less toxic than their synthetic counterparts. Ayurveda [Ayu = life, veda = knowledge] the classical Indian system of medicine is based on the principle of balance and counterbalance and it extensively uses plant-derived compound formulations for the treatment of various ailments. AME has been traditionally used in Ayurveda as a cardiotoxic drug for treating various heart ailments. Therefore the present study was designed to evaluate the cardioprotective effect of bael (*Aegle marmelos*) in mice treated with doxorubicin.

Elevation of serum CK has been reported to be a reliable indicator of DOX-induced cardiotoxicity [68]. The DOX treatment significantly increased the acute cardiotoxicity manifested by elevated levels of serum CK-MB, LDH, GOT and GPT. A similar rise in these enzymes has been previously reported [34,38,39,63]. AME has been able to reduce the DOX-induced cardiotoxicity in mice, as indicated by a significant reduction in the serum GOT, GPT, CK-MB and LDH. These findings are in agreement with earlier studies where AME was reported to reduce the CK-MB and LDH levels significantly and protect rat myocardium against lipid peroxidation and membrane damage [45,49]. The isolated periplogenin from *Aegle marmelos* has been found to reduce these enzymes in rat serum [69]. In earlier studies AME has been reported to stabilize cardiac cell membranes and preserve their integrity by regulating cardiac enzyme release [42,44]. Similarly, other pharmacological agents such as antarth (a composite herbal preparation), curcumin, lycopene, naringin, tomato extract, *Phyllanthus urinaria* and *Centella asiatica* have been reported



**Figure 5:** Kaplan Meir's estimate of survival of EAC bearing mice treated with AME in combination with DOX.



**Figure 6:** Effect of AME on the median survival time (MST) and average survival time (AST) of EAC mice treated with DOX.



to protect against DOX-induced cardiotoxicity [34-39]. ICRF-187, 7-mono-hydroxyethylrutoside and Frederine have also been reported to reduce DOX-induced cardiotoxicity [67,70-72]. The polyphenol, resveratrol, has been reported to protect against the DOX-induced elevation in LDH, and GOT in Wistar rats [73]. The bioflavonoid naringin has been reported to protect DOX-induced cardiotoxicity by reducing the activity of GOT, GPT, CK-MB and LDH in mice [39].

Generation of free radicals with subsequent lipid peroxidation in cardiac tissues is an important mechanism by which DOX induces cardiotoxicity [3,74]. The increase in MDA is likely to follow DOX-induced free radicals generation with decrease in antioxidant enzymes. GSH is involved in both enzymatic and non-enzymatic detoxification of a variety of free radicals including reactive oxygen species; several investigations have explored the role of GSH in cardiac protection against DOX-induced toxicity [75,76]. Administration of exogenous GSH to mice significantly inhibited the acute myocardial toxicity of DOX [75]. Several studies have shown that natural ingredients like garlic, *Terminalia arjuna* and powerful antioxidants like curcumin, proboccol, natural flavanoids and captopril have been reported to protect against DOX-induced toxicity [31,33,34,39,77]. The damage to mouse myocardium may be due to DOX-induced oxidative stress in the present study. AME has been reported to scavenge various free radicals earlier [46] and the reduced cardiotoxicity may be due the ability of AME to scavenge DOX-induced free radicals *in vivo*.

In the present study a single dose of DOX (15 mg/kg) caused a significant increase in the myocardial TBARS and subsequent decrease in myocardial GSH, catalase, SOD and GSHPx at all the post-DOX treatment times indicating an increase in oxidative stress. Our results are in agreement with earlier studies where DOX has been reported to decrease the concentration of cardiac GSH and increase in TBARS [34,69,78]. AME administration before DOX treatment significantly raised the GSH, catalase, SOD and GSHPx levels and a consequent decline in the TBARS induced by DOX at all post DOX treatment times. Increase in catalase activity is accompanied by increase in SOD and GSHPx activities in the myocardial tissue of mice administered with AME before DOX treatment. Any increase in SOD activity of the tissue is beneficial in the event of free radical generation. However it has been reported that a rise in SOD activity, without a concomitant rise in catalase or GSHPx activity might be detrimental [79]. It is due to the fact that the SOD generates hydrogen peroxide, which is a cytotoxic metabolite and has to be scavenged by catalase or GSHPx. The cardioprotective effect of AME might be attributed to increase in the GSH, catalase, SOD and GSHPx activities with subsequent decline in the TBARS in the present study. An identical effect has been observed earlier, where AME and antarth treatment elevated the activity of antioxidant enzymes accompanied by a decline in the TBARS in isoproterenol treated rats or DOX treated mice [38,45,49]. AME has also been reported to elevate antioxidant status in irradiated mice [80,81]. A similar rise in antioxidants has been reported in the heart of mice receiving naringin before DOX treatment [39].

DOX is known to cause a decrease in heart function in both humans and experimental laboratory animals [82, 83]. Electrocardiographic changes associated with DOX-induced cardiomyopathy initially include various reversible arrhythmias, most commonly sinus tachycardia [84,85]. ECG profiles after two weeks of chronic DOX treatment in mice showed a largest peak, which represents depolarization of ventricular myocardium resulting in heart contraction in the present study. Immediately following the main peaks is the T wave which represents the repolarization of the heart. Broadening and decreasing T

wave, correlates with the development of DOX-induced cardiotoxicity in mice [83]. DOX treatment widened the ST intervals in mice. An identical effect has been observed in rats treated with isoproterenol [49]. AME pretreatment significantly reduced the ST interval and restored it to almost normal (Figure 2). A similar effect has been observed in isoproterenol-treated rats with marmesinin, an active component present in AME [49]. Likewise, simvastatin has been reported to significantly reduce the ST interval and restore heart beat in DOX treated rats [86]. Further AME has been reported to significantly reduce the ratio of morphologically changed myocardial cells originated from calcium load [44]. The widening of ST interval in DOX treatment may be explained by prolongation of action potential. The action potential is prolonged in Purkinje fibers after incubation with DOX [87].

The diagnostic test with greatest specificity and sensitivity for DOX-induced cardiomyopathy is endomyocardial biopsy [88]. The endomyocardial biopsy from the ventricle shows typical histopathological changes like loss of myofibrils, distention of sarcoplasmic reticulum, and vacuolization of the myocardial cells. Marked tissue injury with subendocardial loss of muscles and accumulation of acute inflammatory cells surrounded by mild edema after DOX treatment alone, whereas only focal necrosis of muscle fiber with moderate edema was noted after AME pretreatment indicating protection against DOX-induced cardiac injury. An identical effect has been reported by garlic and tomato against the DOX-induced histological alterations in the cardiac muscles [33,35].

We were also interested to know whether AME treatment alters the antineoplastic action of DOX and our studies on EAC mice indicate that AME treatment did not interfere with normal tumor development, as the MST and AST remained unchanged in this group when compared with the non-AME treated controls. A Similar effect has been observed earlier in EAC mice receiving antarth or naringin [38,39]. Our results suggest that use of AME and DOX may be a good paradigm to reduce DOX-induced cardiotoxicity and utilize the full antineoplastic action of DOX in clinical situation.

The exact mechanism of protection by AME against the doxorubicin-induced cardiotoxicity is not known. The AME is a pleotropic molecule, which may have utilized multiple putative mechanisms to protect against the DOX-induced myocardial toxicity. The DOX induces free radicals and scavenging/inhibition of free radical generation by DOX seems to one of the important mechanisms of reduction in the myocardial injury. AME has been reported to scavenge free radicals in a concentration dependent manner [46]. The increased antioxidant status indicated by the elevation in GSH, catalase, superoxide dismutase, and GSHPx may have also played a crucial role in protecting heart against DOX-induced toxicity. The DOX act by inhibiting the action of topoisomerase -II enzyme and fixing the damage into the DNA and AME would have restored the action of topoisomerase -II enzyme thereby reducing the DNA damage. Our earlier studies have shown that AME reduced the DOX-induced DNA damage [47]. The DOX has been reported to form covalent adducts with DNA particularly 8-OHdG and mtDNA adducts in rats [89, 90]. In our earlier study we have also reported that DOX-induced 8-OHdG DNA adducts in the mice heart [39] and inhibition of DNA adduct formation by AME could also be responsible for reduction in the DOX-induced cardiotoxicity. Naringin has been reported to protect mice heart by reducing DOX-induced 8-OHdG DNA adducts earlier [39]. Poly (ADP-ribose) polymerase (PARP) overactivation has been reported as a major cause of myocardial injury as well as damage to other tissues and DOX treatment has been found to increase PARP activation in mice heart [39,91]. The AME pretreatment may have protected mice heart by

suppressing the DOX-induced activation of PARP in the present study. DOX increases the activation of NF- $\kappa$ B in cultured cardiomyocytes and inhibition of NF- $\kappa$ B by AME may have inhibited the inflammation and thereby reduced the DOX-induced cardiotoxicity [92,93].

Bael has been reported to contain aegeline, aegelenine, marmelosine, marmelin/ marmesinin, periplogenin, o-methyl hayordinol, alloimperratorin methyl ester, o-isopentanyl hayordinol, linoleic acid, cineole, p-cymene, citronella, citral, cuminaldehyde, D-limonene, eugenol, tannins like ellagic acid and gallic acid, phlobatannins, flavon-3-ols, rutin, leucoanthocyanins, anthocyanins and flavonoid glycoside [43]. Most of these compounds have been reported to possess antioxidative and free radical scavenging activities [69,94,95]. The observed increase in antioxidant status may be due to the presence of the above components in AME, which would have restored the "endogenous antioxidant reserves" and thus protected against DOX-induced cardiotoxicity. The reaction of endogenous antioxidants has been reported to improve myocardial structure and function. Although mechanisms for AME-induced increase in antioxidants are not clear, the study clearly demonstrates that AME may have protected mice heart by acting as an antioxidant as well as by promoting endogenous antioxidants.

Our study demonstrates that AME protected mice against the DOX-induced cardiotoxicity by scavenging of free radicals and raising the antioxidant status of mice heart. The other plausible mechanism of cardidprotection by bael may be due to restoration of topoisomerase -II enzyme activity, reduction in the DOX-induced DNA damage, suppression of DNA adduct formation, PARP and NF- $\kappa$ B activation. The AME protected mouse heart without interfering with the DOX antineoplastic activity, suggesting that AME may be a suitable candidate to reduce DOX-induced toxicity in clinical situations.

#### Acknowledgements

The financial support from the Indian Council of Medical Research, Government of India, New Delhi to carry out this study is thankfully acknowledged.

#### References

1. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, et al. (1969) Adriamycin, 14- hydroxydaunomycin, a new antitumor antibiotic from *S. peuceetii* var. caesius. *Biotechnol Bioeng* 9: 1101– 1110.
2. Bachur NR, Gordon SL, Gee MV, Kon H (1979) NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. *Proc Natl Acad Sci U S A* 76: 954-957.
3. Doroshow JH (1983) Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. *Cancer Res* 43: 4543-4551.
4. Singal PK, Iliskovic N, Li T, Kumar D (1997) Adriamycin cardiomyopathy: pathophysiology and prevention. *FASEB J* 11: 931-936.
5. Halliwell B, Gutteridge JMC (1989) *Free Radicals in Biology and Medicine*. (2nd edn), Oxford University Press, New York.
6. Olson RD, Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. *FASEB J* 4: 3076-3086.
7. Myers C (1998) The role of iron in doxorubicin-induced cardiomyopathy. *Semin Oncol* 25: 10-14.
8. Carter SK (1975) Adriamycin-a review. *J Natl Cancer Inst* 55: 1265-1274.
9. Martin WM, McNally NJ (1980) Cytotoxicity of adriamycin to tumour cells in vivo and in vitro. *Br J Cancer* 42: 881-889.
10. Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? *Semin Oncol* 19: 670-686.
11. Zunino F, Capranico G (1990) DNA topoisomerase II as the primary target of anti-tumor anthracyclines. *Anticancer Drug Des* 5: 307-317.
12. Kizek R, Adam V, Hrabeta J, Eckschlager T, Smutny S, et al. (2012) Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances. *Pharmacol Ther* 133: 26-39.
13. Schwartz RG, Jain D, Storozynsky E (2013) Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. *J Nucl Cardiol* 20: 443-464.
14. Perego P, Corna E, De Cesare M, Gatti L, Polizzi D, et al. (2001) Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. *Curr Med Chem* 8: 31-37.
15. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, et al. (2009) Doxorubicin: the good, the bad and the ugly effect. *Curr Med Chem* 16: 3267-3285.
16. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. *Cancer* 32: 302-314.
17. Wallace KB (2003) Doxorubicin-induced cardiac mitochondriopathy. *Pharmacol Toxicol* 93: 105-115.
18. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, et al. (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. *J Mol Cell Cardiol* 52: 1213-1225.
19. Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES (1973) Cardiac ultrastructural changes induced by daunorubicin therapy. *Cancer* 32: 771-788.
20. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. *N Engl J Med* 339: 900-905.
21. Minotti G, Cairo G, Monti E (1999) Role of iron in anthracycline cardiotoxicity: new tunes for an old song? *FASEB J* 13: 199-212.
22. Tacar O, Sriamornsak P, Dass CR (2013) Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. *J Pharm Pharmacol* 65: 157-170.
23. Kaul N, Siveski-Iliskovic N, Hill M, Slezak J, Singal PK (1993) Free radicals and the heart. *J Pharmacol Toxicol Methods* 30: 55-67.
24. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C (2002) Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. *Cancer Res* 62: 4592-4598.
25. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H (1990) Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. *Pharmacol Ther* 47: 219-231.
26. Singal PK, Kirshenbaum LA (1990) A relative deficit in antioxidant reserve may contribute in cardiac failure. *Can J Cardiol* 6: 47-49.
27. Green D, Bensely D, Schein P (1994) Preclinical evaluation of WR-151327: an orally active chemotherapy protector. *Cancer Res* 54: 738-741.
28. Seifert CF, Nesser ME, Thompson DF (1994) Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. *Ann Pharmacother* 28: 1063-1072.
29. Williams GA, Johnson JR, Burke J (1992) FDA oncology drugs advisory committee review of Zinecard (dexrazoxane, ADR-528, ICRF-187). Rock-ville.
30. Nasa Y, Hashizume H, Hoque AN, Abiko Y (1993) Protective effect of crataegus extract on the cardiac mechanical dysfunction in isolated perfused working rat heart. *Arzneimittelforschung* 43: 945-949.
31. Dwivedi S, Agarwal MP (1994) Antianginal and cardioprotective effects of Terminalia arjuna, an indigenous drug, in coronary artery disease. *J Assoc Physicians India* 42: 287-289.
32. Patel V, Banu N, Ojha JK, Malhotra OP, Udupa KN (1982) Effect of indigenous drug (Pushkarmula) on experimentally induced myocardial infarction in rats. *Act Nerv Super (Praha) Suppl* 3: 387-394.
33. Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, et al. (2003) Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. *BMC Pharmacol* 23: 16.
34. Venkatesan N (1998) Curcumin attenuation of acute adriamycin myocardial toxicity in rats. *Br J Pharmacol* 124: 425-427.
35. Karimi G, Ramezani M, Abdi A (2005) Protective effects of lycopene and tomato extract against doxorubicin-induced cardiotoxicity. *Phytother Res* 19: 912-914.



36. Chularojmontri L, Wattanapitayakul SK, Herunsalee A, Charuchongkolwongse S, Niomsakul S, et al. (2005) Antioxidative and cardioprotective effects of *Phyllanthus urinaria* L. on doxorubicin-induced cardiotoxicity. *Biol Pharm Bull* 28: 1165-1171.
37. Gnanapragasam A, Ebenezar KK, Sathish V, Govindaraju P, Devaki T (2004) Protective effect of *Centella asiatica* on antioxidant tissue defense system against adriamycin induced cardiomyopathy in rats. *Life Sci* 2004 Dec 17;76(5): 585-597.
38. Jagetia GC, Reddy TK, Malagi KJ, Nayak BS, Naidu MB, et al. (2005) Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity. *Phytother Res*. 19(9): 772-778.
39. Jagetia GC, Reddy TK (2014) The grape fruit flavonone naringin protects mice against doxorubicin-induced cardiotoxicity. *J Mol Biochem* 3: 34-49.
40. Das AV, Padayatti PS, Paulose CS (1996) Effect of leaf extract of *Aegle marmelos* (L.) Correa ex Roxb. on histological and ultrastructural changes in tissues of streptozotocin induced diabetic rats. *Indian J Exp Biol* 34: 341-345.
41. Seema PV, Sudha B, Padayatti PS, Abraham A, Raghu KG, et al. (1996) Kinetic studies of purified malate dehydrogenase in liver of streptozotocin-diabetic rats and the effect of leaf extract of *Aegle marmelos* (L.) Correa ex Roxb. *Indian J Exp Biol* 34: 600-602.
42. Haravey SK (1968) A preliminary communication of the action of *Aegle marmelos* (Bael) on heart. *Indian J Med Res* 56: 327-331.
43. Rastogi RM, Mehrotra BN (1990) Compendium of Indian medicinal plants (Central drug research Institute Lucknow India) 1: 388-389.
44. Kakiuchi N, Senaratne LR, Huang SL, Yang XW, Hattori M, et al. (1991) Effects of constituents of Bael (*Aegle marmelos*) on spontaneous beating and calcium-paradox of myocardial cells. *Planta Med* 57: 43-46.
45. Rajadurai M, Prince PS (2005) Comparative effects of *Aegle marmelos* extract and alpha-tocopherol on serum lipids, lipid peroxides and cardiac enzyme levels in rats with isoproterenol-induced myocardial infarction. *Singapore Med J* 46: 78-81.
46. Jagetia GC, Venkatesh P, Baliga MS (2003) Evaluation of the radioprotective effect of *Aegle marmelos* (L.) Correa in cultured human peripheral blood lymphocytes exposed to different doses of gamma-radiation: a micronucleus study. *Mutagenesis* 18(4): 387-393.
47. Venkatesh P, Shantala B, Jagetia GC, Rao KK, Baliga MS (2007) Modulation of doxorubicin-induced genotoxicity by *Aegle marmelos* in mouse bone marrow: a micronucleus study. *Integr Cancer Ther* 6: 42-53.
48. Arul V, Kumaraguru S, Dhananjayan R (1999) Effects of aegeline and lupeol—the two cardioactive principles isolated from the leaves of *Aegle marmelos* Corr. *J Pharm Pharmacol* 51(S): 252.
49. Vimal V, Devaki T (2004) Linear furanocoumarin protects rat myocardium against lipidperoxidation and membrane damage during experimental myocardial injury. *Biomed Pharmacother* 58: 393-400.
50. Suffness M, Douros J (1979) Drugs of plant origin. In *Methods in cancer Research*. ED, De Vita VT. 16: 73-94.
51. Bergmeyer HU, Bernet E (1974) Lactate dehydrogenase isoenzymes UV assay after separation on DEAE sephadex, In *methods of enzymatic analysis*, Bergmeyer HU (ed.), Verlag Chemie, Weinheim.
52. Kachmar JF, Moss DW (1982) Enzymes, In *fundamentals of clinical chemistry*. Tietz W (ed.) W. B. Saunders, Philadelphia; 565-595.
53. REITMAN S, FRANKEL S (1957) A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. *Am J Clin Pathol* 28: 56-63.
54. Sandermann H Jr, Strominger JL (1972) Purification and properties of C 55 -isoprenoid alcohol phosphokinase from *Staphylococcus aureus*. *J Biol Chem* 247: 5123-5131.
55. Gelvan D, Saltman P (1990) Different cellular targets of Cu- and Fe-catalyzed oxidation observed using a Cu-compatible thiobarbiturate acid assay. *Biochim Biophys Acta* 1035: 353-360.
56. Moron MS, Depierre JW, Mannervik B (1979) Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. *Biochim Biophys Acta* 582: 67-78.
57. Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. *Eur J Biochem* 47: 469-474.
58. Aebi H (1984) Catalase in vitro. *Methods Enzymol* 105: 121-126.
59. Wendel A (1981) Glutathione peroxidase. *Methods Enzymol* 77: 325-333.
60. Billingham M (1991) Role of endomyocardial biopsy in diagnosis and treatment of heart disease. In: M. D. Silver (ed.), *Cardiovascular Pathology*, Ed. 465-1486.
61. Gabrielson KL, Hogue BA, Bohr VA, Cardounel AJ, Nakajima W, et al. (2001) Mitochondrial toxin 3-nitropropionic acid induces cardiac and neurotoxicity differentially in mice. *Am J Pathol* 159: 1507-1520.
62. Geran RI, Greenberg NH, Mac Donald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems, *Cancer Chemotherapy Reports* , 1-85.
63. Van Acker SA, Kramer K, Voest EE, Grimbergen JA, Zhang J, et al. (1996) Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A model to test potential protectors. *Cancer Chemother Pharmacol* 38: 95-101.
64. Hoppers GA, Eisenhauer EA, de Vries EG (1999) The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. *Br J Cancer* 80: 629-638.
65. Kalam K, Marwick TH (2013) Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. *Eur J Cancer* 49: 2900-2909.
66. Ferguson LR, Pearson AE (1996) The clinical use of mutagenic anticancer drugs. *Mutat Res* 355: 1-12.
67. van Acker FA, van Acker SA, Kramer K, Haenen GR, Bast A, et al. (2000) 7-monohydroxyethylrutin protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. *Clin Cancer Res* 6: 1337-1341.
68. Kang YJ, Chen Y, Yu A, Voss-McCowan M, Epstein PN (1997) Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. *J Clin Invest* 100: 1501-1506.
69. Panda S, Kar A (2009) Periplogenin-3-O- -D-glucopyranosyl -(1->6)-D-glucopyranosyl- -(1->4) -D-cymaropyranoside, isolated from *Aegle marmelos* protects doxorubicin induced cardiovascular problems and hepatotoxicity in rats. *Cardiovasc Ther* 27: 108-116.
70. Sparano JA (1998) Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. *Semin Oncol* 25: 66-71.
71. Speyer JL, Green MD, Zeleniuch-Jacquette A, Wernz JC, Rey M, et al. (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. *J Clin Oncol* 10: 117-127.
72. van Acker FA, Boven E, Kramer K, Haenen GR, Bast A, et al. (2001) Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity. *Clin Cancer Res* 7: 1378-1384.
73. Tatlidede E, Sehirli O, Velioglu-Ozyildirim A, Cetinel S, Yeşen BC, et al. (2009) Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. *Free Radic Res* 43: 195-205.
74. Bahorun T, Soobrattee MA, Ramma VL, Aruoma OI. (2006) Free Radicals and Antioxidants in Cardiovascular Health and Disease. *Internet Journal of Medical Update* 1(2): 25-41.
75. Yoda Y, Nakazawa M, Abe T, Kawakami Z (1986) Prevention of doxorubicin myocardial toxicity in mice by reduced glutathione. *Cancer Res* 46: 2551-2556.
76. Villani F, Galimberti M, Monti E, Piccinini F, Lanza E, et al. (1990) Effect of glutathione and N-acetylcysteine on in vitro and in vivo cardiac toxicity of doxorubicin. *Free Radic Res Commun* 11: 145-151.
77. al-Gharably NM (1996) Effect of probucol on the cytological and biochemical changes induced by adriamycin in Swiss albino mice. *Res Commun Mol Pathol Pharmacol* 94: 289-303.
78. Osman AM, Al-Shabanah OA, Al-Harbi MM, Al-Gharably NM, Al-Bekairi AM (1993) Effect of desferrioxamine on doxorubicin-induced cardio and hemato-toxicity in normal mice. *Med Sci Res* 21: 193-194.
79. Harman D (1991) The aging process: major risk factor for disease and death. *Proc Natl Acad Sci U S A* 88: 5360-5363.

80. Jagetia GC, Venkatesh P, Baliga MS (2004) Evaluation of the radioprotective effect of bael leaf (*Aegle marmelos*) extract in mice. *Int J Radiat Biol* 80: 281-290.
81. Jagetia GC, Venkatesh P (2005) Radioprotection by oral administration of *Aegle marmelos* (L.) Correa in vivo. *J Environ Pathol Toxicol Oncol* 24: 315-332.
82. Goebel M, Kaplan E (1992) Anthracycline-induced cardiotoxicity – a review. *Onkologie* 1:198-204.
83. Danesi R, Del Tacca M, Soldani G (1986) Measurement of the S alpha T segment as the most reliable electrocardiogram parameter for the assessment of adriamycin-induced cardiotoxicity in the rat. *J Pharmacol Methods* 16: 251-259.
84. Bristow MR, Billingham ME, Mason JW, Daniels JR (1978) Clinical spectrum of anthracycline antibiotic cardiotoxicity. *Cancer Treat Rep* 62: 873-879.
85. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, et al. (1979) Adriamycin cardiotoxicity: a survey of 1273 patients. *Cancer Treat Rep* 63: 827-834.
86. Naiyra A, Elbaky A., Ali AA, Ahmed RA (2010) Cardioprotective effect of simvastatin on doxorubicin-induced oxidative cardiotoxicity in rats. *J Basic Appl Sci* 6(1): 29-38.
87. le Marec H, Spinelli W, Rosen MR (1986) The effects of doxorubicin on ventricular tachycardia. *Circulation* 74: 881-889.
88. Mason JW, Bristow MR, Billingham ME, Daniels JR (1978) Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. *Cancer Treat Rep* 62: 857-864.
89. Serrano J, Palmeira CM, Kuehl DW, Wallace KB (1999) Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. *Biochim Biophys Acta* 1411: 201-205.
90. Zhou S, Palmeira CM, Wallace KB (2001) Doxorubicin-induced persistent oxidative stress to cardiac myocytes. *Toxicol Lett* 121: 151-157.
91. Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, et al. (2002) Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. *J Pharmacol Exp Ther* 300: 862-867.
92. Guo RM, Xu WM, Lin JC, Mo LQ, Hua XX, et al. (2013) Activation of the p38 MAPK/NF- $\kappa$ B pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells. *Mol Med Rep* 8: 603-608.
93. Li D, Li J, An Y, Yang Y, Zhang SQ (2013) Doxorubicin-induced apoptosis in H9c2 cardiomyocytes by NF- $\kappa$ B dependent PUMA upregulation. *Eur Rev Med Pharmacol Sci* 17: 2323-2329.
94. Korkina LG, Afanas'ev IB (1997) Antioxidant and chelating properties of flavonoids. *Adv Pharmacol* 38: 151-163.
95. Vidhya N, Devaraj SN (1999) Antioxidant effect of eugenol in rat intestine. *Indian J Exp Biol* 37: 1192-1195.